NRSN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
NeuroSense Therapeutics Ltd (NRSN) is not a strong buy at this time for a beginner investor with a long-term strategy. The stock faces significant challenges, including non-compliance with Nasdaq listing requirements and weak financial performance. While there are some positive developments, such as patent protection for PrimeC, the lack of strong trading signals, bearish technical indicators, and poor financial metrics make it unsuitable for immediate investment.
The MACD is slightly positive but contracting, indicating weak momentum. RSI is neutral at 39.617, providing no clear signal. Moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading below key pivot levels. The stock has a 90% chance to decline by -2.08% in the next day and a minimal chance of significant gains in the next week or month.
This supports its development for ALS and Alzheimer's disease, which could be a long-term growth driver.
The company has received warnings from Nasdaq for non-compliance with minimum bid price and market value requirements, which poses a risk of delisting. Additionally, the stock has been trading below $1 for an extended period, reflecting weak investor confidence.
In Q4 2024, the company reported no revenue growth (0% YoY), a net income drop of -100% YoY, and an EPS decline of -40.54% YoY. These metrics highlight poor financial health and lack of profitability.
Roth Capital initiated coverage with a Buy rating and a $3 price target, citing optimism about PrimeC's potential for ALS treatment. However, this is a long-term projection, and the stock's current challenges overshadow this positive outlook.
